Anti-HER2 MAbs have a limited impact on tumor growth in Rag1−/− mice, which lack T and B lymphocytes [26], and the depletion of CD8+ T cells abrogates its antitumor activity in BALB/c mice bearing TUBO or H2N100 tumors [25, 26]. This evidence concerns the gene CD8A and neoplasm.